EGAGenomicsNanostring cancer pathway, Nanostring Cancer Immune, ILLUMINA, Affymetrix GeneChip® Human Transcriptome Array 2.0, Illumina HiSeq 4000Otherhttps://ega-archive.org/studies/EGAS00001002501EGAEGA study EGAS00001002501RNAseq dataset of 34 samples (6 normals, 7 stroma-enriched, 21 malignant cells-enriched) from patients with resected pancreatic ductal carcinoma.Transcriptome profiling by arrayTranscriptome profiling by array after Kit Nugen OvationTranscriptome profiling by array after Kit FFPEsensation WT AffymetrixGenotyping by arrayrestrictedEGACarcinomas, pancreatic duct adenocarcinoma, Carcinoma, Pancreatic Duct Cell Carcinoma, pancreas tubular adenocarcinoma, Pancreas Duct-Cell Carcinomas, wide/broad, Genomes, Ductal Carcinoma, malignant neoplasm of duct of Wirsung, Pancreas Duct-Cell, pancreatic ductal adenocarcinoma, Duct-Cell Carcinoma, Duct-Cell Carcinomas, whole genome, broad, Client, Pancreas, ductal adenocarcinoma of pancreas, pancreas ductal adenocarcinoma, Duct-Cell Carcinoma of the Pancreas, Pancreas Duct-Cell Carcinoma, Ductal Carcinomas, wide, Ductal, Duct Cell Carcinoma of the Pancreas., Duct Cell Carcinoma, pancreatic ductal carcinoma, ductal adenocarcinoma of the pancreas, Patient, pancreatic tubular adenocarcinoma, Clients, Pancreatic Ductal Carcinomas, Ductal Carcinoma of the Pancreas, microarray, Pancreatic Ductal Carcinoma, PDAC, pancreatic duct cancer, Pancreatic, Pancreatic DuctalFormol, Biological Markers, Viral Marker, Surrogate Endpoints, lymphoid dendritic cell, Clinical Markers, Laboratory, type 2 DC, selection process, Clinical Marker, Pancreas Duct-Cell, Duct-Cell Carcinoma, Biochemical, Duct-Cell Carcinomas, Gene, Endpoint, pancreas, broad, Serum, Surrogate End Points, Pathologist, Surrogate Markers, Ductal, Laboratory Markers, Duct Cell Carcinoma, plasmacytoid monocyte, Biological, Methanal, Parafilm, MR1, MR-1, Pancreatic Ductal Carcinomas, PDAC, average, study, Biomarker, pancreas tubular adenocarcinoma, intestinum duodenum, Gene Expressions, Clinical, Genomes, Biological Marker, Formaldehyd, Tissue, Oxomethane, KIPP1184, Expressions, Duodenums, anterior intestine, Immunologic Markers, pancreatic ductal carcinoma, Immune, Markers, Formalin, Clients, Viral Markers, Pancreatic Ductal Carcinoma, interferon-producing cell, Expression, Immunologic Marker, Biologic, Carcinoma, upper intestine, Pancreatic Duct Cell Carcinoma, T-associated plasma cell, Viral, wide/broad, total RNA extract, Surrogate Endpoint, Immune Markers., Ductal Carcinoma, pancreatic ductal adenocarcinoma, Serum Markers, DC2, End Point, FPD1, Biochemical Markers, DYT8, Biologic Marker, Client, Cell, ductal adenocarcinoma of pancreas, pancreas ductal adenocarcinoma, Immune Marker, Pancreas Duct-Cell Carcinoma, Ductal Carcinomas, plasmacytoid T cell, ductal adenocarcinoma of the pancreas, dodecadactylon, Marker, Surrogate End Point, Ductal Carcinoma of the Pancreas, TAHCCP2, FORMALIN, pancreatic duct cancer, proximal intestine, Pancreatic, fixed, Biologic Markers, Carcinomas, pancreatic duct adenocarcinoma, Serum Marker, Pancreas Duct-Cell Carcinomas, End Points, Surrogate, malignant neoplasm of duct of Wirsung, PDC, Endpoints, whole genome, Immunologic, Laboratory Marker, Pancreas, Methylene oxide, Surrogate Marker, Duct-Cell Carcinoma of the Pancreas, wide, Oxomethylene, Patient, pancreatic tubular adenocarcinoma, PKND1, Biochemical Marker, BRP17, pDC, microarray, Pancreatic Ductal, IPC, stromal connective tissue, Duct Cell Carcinoma of the PancreasfalseGenome-wide expression profiles to compare array-based, RNAseq and NanoString technologies in patients with resected pancreatic ductal carcinoma.Using formalin-fixed paraffin embedded (FFPE) tissues collected prospectively in patients with resected pancreatic ductal carcinoma (PDC) we generated genome-wide expression profiles to compare array-based, RNAseq and NanoString technologies. Samples included in the study were collected 17 patients. After careful selection by the pathologist of 17 malignant cells-enriched, 7 stroma-enriched, and 6 normal (normal pancreas in 4 cases and normal duodenum in 2 cases) regions, sections were macrodissected, and total RNA extracted. Two additional FFPE-frozen matched-paired PDAC from our local Biobank were included. Our study represents the most extensive work comparing three technologies to generate gene expression profiles from FFPE samples, and provides technical guidance for future biomarker studies in samples collected prospectively in the context of clinical trials.2017-07-26 15:39:30EGAS000010025019606EGAD00010001275EGAD00010001273EGAD00010001276EGAD00010001274EGAD00001003399EGAC00001000382